The Insides Company's flagship product, The Insides® System, is a medical device that enables chyme to be reinfused into the intestine for enterostomy and enterocutaneous fistula patients.
The Insides System is commercially available in the United Kingdom, Europe, and New Zealand.
*The Insides System is not available in other markets.
-min.png)
The Insides Company is founded by world-leading pioneers in gut surgery, and is commercialised by med-tech veterans. The Insides System is now being used in may of the world's leading international intestinal failure centres.
Please contact us today to learn about how The Insides System can impact your Intestinal Failure patient's journey to recovery.
Professor Ian Bissett
Co-Founder & Chief Medical Officer
“Encourage the formation of double stomas and the consideration of the use of the distal opening for re-infusion of chyme in the setting of an entero-atmospheric fistula.”
Emma Ludlow
Clinical Nurse Specialist Ostomy
"The Insides® System allows me to support, and optimise my patient’s journey to recovery."
Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals.
The enterostomy is typically left open for 6-12 months, and during this time, the chyme that is collected is disposed which can result in intestinal failure
The Insides System, is a chyme reinfusion solution, which enables diverting enterostomy, and enterocutaneous patients to reinfuse chyme back into their intestine, allowing them to recommence oral feeding and reduce length of stay in hospital.
Earlier return to oral feeding1
Patients able to recommence oral feeding
Improved nutritional outcome2
Increase in nutritional risk index by 10.9 (± 9.5) with a 85% reduction in intestinal losses
Improved restoration of gut function3
Limiting gut atrophy and inflammation
Improved renal function4-5
Prevents dehydration and reduces the potential for chronic kidney disease
Improved liver function5-6
53% reduction in plasma liver test abnormalities
Wean off Parenteral Nutrition6
>91% of patients weaned off parenteral nutrition within a median of 2 days (± 9)
.png)
.png){kind=small}
.png){kind=small}
